Swiss - Delayed Quote CHF

Galderma Group N (GALD.SW)

Compare
77.69 -0.51 (-0.65%)
As of 4:40 PM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GALD.SW

Recent News: GALD.SW

View More
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess?)

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess?)
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Galderma Receives U.S. FDA Approval for Nemluvio? (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Galderma Receives U.S. FDA Approval for Nemluvio? (nemolizumab) for Adult Patients Living With Prurigo Nodularis
L’Oreal Buys Stake in Swiss Skincare Company Galderma

L’Oreal Buys Stake in Swiss Skincare Company Galderma
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
Galderma’s Relfydess? (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma’s Relfydess? (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin

Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
Galderma Launches Restylane? VOLYME? in China – One of the World’s Fastest Growing Aesthetics Markets

Galderma Launches Restylane? VOLYME? in China – One of the World’s Fastest Growing Aesthetics Markets
View More

Related Tickers